GCM
AMAM

Ghisallo Capital Management’s Ambrx Biopharma Inc AMAM Stock Holding History

Ghisallo Capital Management’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$203K – 547
2021
Q3 		$203K Sell
15,000
-25,000
-63% -$450K 0.01% 436
2021
Q2 		$784K Buy
+40,000
New +$682K 0.03% 369

Other funds holding AMAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Ghisallo Capital Management's AMAM Position: Q4 2021 in Review

Ghisallo Capital Management sold out of Ambrx Biopharma Inc (AMAM) in Q4 2021, closing a stake of 15,000 shares — an estimated $203K sold.

Ghisallo Capital Management first reported a position in AMAM in Q2 2021 and held it in 2 quarters. The position peaked at $784K in Q2 2021. 16 funds tracked by Wall St. Rank hold AMAM as of Q4 2021.

  • Ghisallo Capital Management reported no remaining Ambrx Biopharma Inc position as of Q4 2021 after selling out during the quarter.
  • Ghisallo Capital Management sold 15,000 Ambrx Biopharma Inc shares in Q4 2021, an estimated $203K.
  • Ghisallo Capital Management first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 2 quarters.
  • Ghisallo Capital Management's Ambrx Biopharma Inc position peaked at $784K in Q2 2021.
  • 16 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q4 2021.

Based on Ghisallo Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.